This document summarizes a trial of Digistain, a new mid-infrared chemical imaging technology for cancer diagnosis. The trial objectives were to test the reproducibility of Digistain and correlate its results with cancer grading by histopathology. The trial achieved strong reproducibility and a strong linear correlation between the Digistain Index and cancer grade. Issues addressed during the trial included folded samples, delays, bad images, and difficulties with invasive samples. The significance of Digistain includes providing objective cancer diagnoses, a quantitative malignancy marker, and contributions to effective treatment and reduced cancer rates.